Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patients
Open Access
- 30 May 2006
- journal article
- research article
- Published by Springer Nature in Journal of Immune Based Therapies and Vaccines
- Vol. 4 (1) , 3
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Comparison of the cost and effectiveness of two strategies for maintaining hepatitis B immunity in hemodialysis patientsVaccine, 2002
- Hepatitis infection in haemodialysis patientsNephrology, 2002
- AM3 (Inmunoferón®) as an adjuvant to hepatitis B vaccination in hemodialysis patientsKidney International, 2002
- Effect of Oral Levamisole Supplementation to Hepatitis B Vaccination on the Rate of Immune Response in Chronic Hemodialysis PatientsNephron, 2000
- Vaccine Recommendations for Patients on Chronic DialysisSeminars in Dialysis, 2000
- Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigenHepatology, 2000
- Low-dose intramuscular revaccination against hepatitis BVaccine, 1996
- Immunomodulation by levamisole in patients with recurrent aphthous ulcers or oral lichen planusJournal of Oral Pathology & Medicine, 1994
- INTRADERMAL VACCINATION AGAINST HEPATITIS BThe Lancet, 1986
- The General Immunopharmacology of LevamisoleDrugs, 1980